X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (42) 42
humans (36) 36
article (23) 23
oncology (22) 22
female (21) 21
male (21) 21
cancer (16) 16
abridged index medicus (15) 15
middle aged (15) 15
aged (14) 14
chemotherapy (11) 11
quality of life (10) 10
squamous-cell carcinoma (10) 10
radiotherapy (9) 9
squamous cell carcinoma (9) 9
adult (8) 8
carcinoma, squamous cell - therapy (8) 8
care and treatment (8) 8
head and neck cancer (8) 8
locally advanced head (7) 7
risk factors (7) 7
survival (7) 7
survivorship (7) 7
united-states (7) 7
usage (7) 7
carcinoma, squamous cell - pathology (6) 6
chemoradiation (6) 6
human papillomavirus (6) 6
neoplasm staging (6) 6
otorhinolaryngology (6) 6
research (6) 6
surgery (6) 6
treatment outcome (6) 6
united states (6) 6
aged, 80 and over (5) 5
breast-cancer (5) 5
complications and side effects (5) 5
epidemiology (5) 5
head and neck neoplasms - therapy (5) 5
human-papillomavirus (5) 5
metastasis (5) 5
neck-cancer (5) 5
oropharyngeal cancer (5) 5
papillomavirus infections (5) 5
patients (5) 5
survivors (5) 5
analysis (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cancer survivors (4) 4
carcinoma (4) 4
cetuximab (4) 4
cohort studies (4) 4
comorbidity (4) 4
head and neck neoplasms - pathology (4) 4
hematology, oncology and palliative medicine (4) 4
immunotherapy (4) 4
medicine, general & internal (4) 4
metastases (4) 4
neoplasms (4) 4
oropharyngeal neoplasms - therapy (4) 4
prognosis (4) 4
radiation-therapy (4) 4
risk (4) 4
seer program (4) 4
sorafenib (4) 4
therapy (4) 4
thyroid cancer (4) 4
united states - epidemiology (4) 4
american society (3) 3
cancer therapies (3) 3
carcinoma, squamous cell - epidemiology (3) 3
carcinoma, squamous cell - mortality (3) 3
carcinoma, squamous cell - virology (3) 3
cell lung-cancer (3) 3
chemoradiotherapy - adverse effects (3) 3
chemoradiotherapy - methods (3) 3
clinical trials (3) 3
databases, factual (3) 3
diagnosis (3) 3
double-blind (3) 3
extracapsular spread (3) 3
follow-up (3) 3
head and neck neoplasms - drug therapy (3) 3
head and neck neoplasms - epidemiology (3) 3
health aspects (3) 3
hpv-related oropharyngeal squamous cell carcinoma (3) 3
humanities (3) 3
late effects (3) 3
lenvatinib (3) 3
mammography (3) 3
medical oncology - standards (3) 3
neck (3) 3
nivolumab (3) 3
oropharyngeal neoplasms - pathology (3) 3
oropharyngeal neoplasms - virology (3) 3
population (3) 3
practice patterns, physicians (3) 3
quality of health care (3) 3
radiology, nuclear medicine & medical imaging (3) 3
randomized-trial (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMJ (Online), ISSN 0959-8146, 2018, Volume 360, p. k793
OBJECTIVE To evaluate rates of serious organ specific immune-related adverse events, general adverse events related to immune activation, and adverse events... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | CHECKPOINT INHIBITORS | PEMBROLIZUMAB | ADVANCED MELANOMA | RISK | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | NIVOLUMAB | ARTHRITIS | DOCETAXEL
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e17775 - e17775
Journal Article
Nature Genetics, ISSN 1061-4036, 02/2019, Volume 51, Issue 2, pp. 202 - 206
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer... 
CTLA-4 BLOCKADE | THERAPY | LANDSCAPE | PD-1 BLOCKADE | GENETICS & HEREDITY | SENSITIVITY | NEOANTIGENS | Usage | Research | Gene mutations | Immunotherapy | Oncology, Experimental | Cancer | Laboratories | Lung cancer | Melanoma | Histology | Metastasis | Gene expression | Cancer therapies | Patients | Survival | Metastases | Next-generation sequencing | Immune checkpoint | Biomarkers | Mutation | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2016, Volume 34, Issue 3_suppl, pp. 25 - 25
25 Background: There are a growing number of breast cancer survivors, and they are often followed by primary care providers (PCP). With limited specialized... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 7_suppl, pp. 51 - 51
51 Background: Survivorship care plans SCPs typically include generic advice for cancer surveillance, management of late effects (LEs), wellness... 
Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 09/2019, Volume 322, Issue 12, pp. 1209 - 1211
This research letter discusses the association between label restrictions by the US Food and Drug Administration on first-line immunotherapy for advanced... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SINGLE-ARM | CISPLATIN-INELIGIBLE PATIENTS | Bladder | Regulatory agencies | Chemotherapy | Bladder cancer | Immunotherapy | Cancer
Journal Article
Journal of Oncology Practice, ISSN 1554-7477, 02/2018, Volume 14, Issue 2, pp. 72 - 76
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 1092 - 1093
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 11/2017, Volume 123, Issue 21, pp. 4114 - 4121
BACKGROUND Patients with recurrent and/or metastatic, radioactive iodine‐refractory thyroid carcinoma have limited treatment options. Sorafenib, an oral kinase... 
anaplastic thyroid cancer | v‐Raf murine sarcoma viral oncogene homolog B (BRAF) mutation | thyroid cancer | sorafenib | mammalian target of rapamycin (mTOR) inhibition | v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation | BROAD-SPECTRUM | II TRIAL | MTOR | LENVATINIB | ONCOLOGY | HISTOLOGIC SUBTYPES | DOUBLE-BLIND | TARGETS | CARCINOMA | PROGRESSION | Niacinamide - analogs & derivatives | Adenocarcinoma, Follicular - radiotherapy | Adenocarcinoma, Follicular - pathology | Humans | Middle Aged | Radiation Tolerance | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Adenocarcinoma, Follicular - genetics | Male | Antineoplastic Agents - therapeutic use | Iodine Radioisotopes - therapeutic use | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adenocarcinoma, Follicular - drug therapy | Aged, 80 and over | Adult | Female | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Drug Administration Schedule | Niacinamide - adverse effects | Treatment Outcome | Thyroid Neoplasms - radiotherapy | Niacinamide - administration & dosage | Disease-Free Survival | Sirolimus - administration & dosage | Thyroid Neoplasms - genetics | Phenylurea Compounds - administration & dosage | Thyroid Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Thyroid Neoplasms - pathology | Temsirolimus | Cancer patients | Care and treatment | Dosage and administration | Thyroid cancer | Drug therapy | TOR protein | Intravenous administration | Mucositis | Toxicity | Anemia | Cytotoxicity | Fatigue | Rapamycin | Metastasis | Cancer therapies | Patients | Metastases | Thyroid carcinoma | Hyperglycemia | Chemotherapy | Inhibitors | Quality | Response rates | Background radiation | Iodine | Cancer | Thyroid | Index Medicus | Abridged Index Medicus
Journal Article
Head & Neck, ISSN 1043-3074, 11/2013, Volume 35, Issue 11, pp. 1534 - 1541
Journal Article
Head & Neck, ISSN 1043-3074, 11/2018, Volume 40, Issue 11, pp. 2321 - 2328
Background We explored if age affects quality of life (QOL) in survivors of locally advanced human papillomavirus (HPV)‐related oropharyngeal squamous cell... 
geriatrics | oropharyngeal cancer | quality of life | human papillomavirus | UNITED-STATES | SURGERY | EQ-5D | POPULATION | RESPONSIVENESS | EUROPEAN ORGANIZATION | CHEMORADIOTHERAPY | NECK-CANCER | OTORHINOLARYNGOLOGY | BODY-MASS | LOCALLY ADVANCED HEAD | CONCURRENT CHEMORADIATION | Ostomy | Squamous cell carcinoma | Human papillomavirus | Oropharyngeal cancer | Questionnaires | Neck | Patients | Age | Quality of life
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 8, pp. 1345 - 1353
BACKGROUND Despite controversy surrounding its benefit, the use of concomitant chemoradiotherapy (CCRT) in patients with oropharyngeal squamous cell carcinoma... 
human papillomavirus (HPV) | cetuximab | chemoradiation | elderly | oropharyngeal squamous cell carcinoma | UNITED-STATES | SURVIVAL | CHEMORADIATION THERAPY | HUMAN-PAPILLOMAVIRUS | NECK-CANCER | RADIATION-THERAPY | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | LOCALLY ADVANCED HEAD | ELDERLY-PATIENTS | CONCURRENT CHEMORADIOTHERAPY | Oropharyngeal Neoplasms - diagnosis | Oropharyngeal Neoplasms - therapy | Chemoradiotherapy - adverse effects | Chemoradiotherapy - methods | Age Factors | Humans | Radiotherapy, Intensity-Modulated - methods | Risk Factors | Oropharyngeal Neoplasms - mortality | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Squamous Cell - therapy | Male | Treatment Outcome | Radiotherapy, Intensity-Modulated - adverse effects | Carcinoma, Squamous Cell - diagnosis | Retreatment | Carcinoma, Squamous Cell - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Female | Aged | Retrospective Studies | Neoplasm Staging | Odds Ratio | Treatment outcome | Chemotherapy | Usage | Analysis | Diagnosis | Throat cancer | Radiotherapy | Health aspects | Cancer | Elderly people | Squamous cell carcinoma | 5-Fluorouracil | Toxicity | Radiation therapy | Patients | Cisplatin | Paclitaxel | Carboplatin | Adults | Toxic diseases | Acute toxicity | Index Medicus | Abridged Index Medicus
Journal Article
JAMA Internal Medicine, ISSN 2168-6106, 10/2017, Volume 177, Issue 10, pp. 1538 - 1539
Journal Article